Clinical trials with 1-acetyl-2-picolinoylhydrazine (NSC-68626) in children.
Thirty-seven children with various malignant neoplasms were treated with 1-acetyl-2-picolinoylhydrazine. Complete regressions were documented in one child with embryonal rhabdomyosarcoma, in one child with generalized histiocytosis-X, and in one child with Hodgkin's disease. One patient had renal failure while receiving the drug but no conclusive cause and effect relationship could be established. Toxic effects otherwise were mild and consisted primarily of nausea and vomiting.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008206:Lymphatic Diseases / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D009918:Orbital Neoplasms / Q000188:drug therapy; D010848:Picolinic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D012208:Rhabdomyosarcoma / Q000188:drug therapy
D000970:Antineoplastic Agents; D010848:Picolinic Acids